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Abstract
Objective—Health-related quality of life (HRQOL) has been found to be associated with overall 
survival in women with ovarian cancer. However, previous studies assessed HRQOL after surgery 
within clinical trial populations only. The study goal was to determine the association of pre-
cancer diagnosis HRQOL with the likelihood of receiving surgery and with overall survival in a 
national, population-based cohort of older women with advanced ovarian cancer.
Methods—The Surveillance, Epidemiology, and End Results (SEER)-Medicare Health 
Outcomes Survey (MHOS) database was queried to identify 374 women aged 65 years and older 
with advanced stage epithelial ovarian cancer from 1998 to 2011. Responses to the Short Form 36 
(SF-36) and Veterans-RAND-12 (VR-12), two single-item global health questions, and Activities 
of Daily Living (ADLs) were abstracted. Multivariable models were used to quantify associations 
of HRQOL and ADL assessments with surgery and overall survival, adjusted for demographic and 
clinical characteristics.
Results—Of 374 women with a HRQOL assessment prior to diagnosis, 199 (53%) underwent 
surgery. Increases in physical and mental HRQOL domains were significantly associated with 
receipt of surgery. The relationship between HRQOL domains and overall survival were not 
statistically significant. For ADLs, only difficulty in toilet use was significantly associated with 
survival.
Conclusion—In this population-based sample of older women with advanced epithelial ovarian 
cancer, pre-diagnosis HRQOL was predictive of receiving surgery, but not of overall survival.
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Introduction
Health-related quality of life (HRQOL) is a patient-reported construct that can be influenced 
by a patient’s clinical status and demographic background.1, 2 In ovarian cancer, measures of 
HRQOL3, 4 have been shown to be associated with overall survival in clinical trial 
populations. With respect to HRQOL in ovarian cancer, previous studies have used HRQOL 
data collected from newly enrolled, post-operative clinical trial patients. As this time point is 
both after diagnosis and initial surgery, it may not reflect true baseline HRQOL. Cancer 
clinical trial populations are also limited by underrepresentation of racial/ethnic minorities,5 
low-income populations,6, 7 and older adults5 – three demographic factors that are 
significantly associated with HRQOL. As the incorporation of patient-reported outcomes 
becomes more important in cancer care,8 population-based data may improve 
generalizability of the relationships between HRQOL and outcomes.
To date, whether pre-diagnostic and pre-treatment patient-reported HRQOL is associated 
with overall survival among ovarian cancer patients is unknown. The relationship between 
pre-diagnosis HRQOL and whether or not surgery is performed is also unknown. Given that 
surgery is the strongest mediator of overall survival in ovarian cancer, the relationship 
between HRQOL and surgery may help explain how HRQOL relates to survival. The 
objective of our study was to use a nationally representative, population-based sample to 
evaluate associations between pre-cancer diagnosis HRQOL and patient-reported functional 
status with receipt of surgery and with overall survival in older women with advanced 
epithelial ovarian cancer in the United States (U.S.).
Methods
Data
The study used the SEER-MHOS dataset (Surveillance, Epidemiology, and End Results 
(SEER)-Medicare Health Outcomes Survey (MHOS), a publically available linked resource 
of patient-reported HRQOL indicators and cancer outcomes, starting with cohorts from 1998 
through 2013. The SEER program includes 18 cancer registries collecting information on 
newly diagnosed cases within SEER geographic regions including 26% of the U.S. 
population.9 The Medicare Health Outcomes Survey (MHOS) is a questionnaire distributed 
annually to 1,000 to 1,200 randomly selected individuals from each managed care 
organization in the Medicare Advantage Program.9 A baseline MHOS along with a follow-
up survey two years later is administered if beneficiaries remain in the same managed care 
organization.9 This study included 14 MHOS cohorts from 1998 to 2013. As Medicare 
Advantage plans are not represented in all SEER regions, the SEER-MHOS dataset includes 
representations of beneficiaries from Connecticut, Hawaii, Iowa, New Mexico, Utah, 
Kentucky, Louisiana, New Jersey, California, Detroit, Atlanta, Seattle-Puget Sound, and 
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rural Georgia..9 Institutional Review Board permission was obtained from the University of 
North Carolina at Chapel Hill.
Participants
We identified 588 women with ovarian cancer, diagnosed between 1998 and 2011, whose 
first SEER-confirmed cancer diagnosis occurred after completing a baseline or follow-up 
MHOS. Of these women, we excluded 110 (18%) who did not have epithelial histology. 
Histology classifications included were ‘epithelial neoplasm’, ‘adenocarcinoma’, and 
‘serous, mucinous, or cystic’ types. Of the remaining 478 women, 12 (2.5%) were excluded 
due to lack of diagnostic confirmation of ovarian cancer in SEER and 97 (20%) were 
excluded because they did not have advanced (distant) stage disease. As such, the final 
sample included 374 diagnostically confirmed women with incident advanced stage ovarian 
cancer 65 years and older.
Covariates
Self-reported covariates included age at diagnosis, race, marital status, highest level of 
education completed, smoking status, SEER geographic region, household income, whether 
or not they owned a home, and pre-existing comorbid conditions. Comorbid conditions 
included hypertension, heart disease, stroke, chronic obstructive pulmonary disease, 
inflammatory bowel disease, arthritis, sciatica, and diabetes. We controlled for whether the 
MHOS was completed by a proxy (e.g., spouse or caregiver), as this may indicate poor 
health status or low literacy. In addition, we adjusted for MHOS mode of administration 
(paper or telephone) and year of diagnosis. Due to reporting restrictions as outlined by the 
SEER-MHOS data use agreement, cell sizes below 11 are suppressed.
Outcomes Measures
Surgery—Receipt of surgery (as reported in SEER) was classified as yes or no. Surgery 
was chosen as a measurable outcome due to the known strong association between receipt of 
surgery and overall survival and the lack of data on how HRQOL may relate to who receives 
surgery. Overall Survival: Whether or not a woman died was reported via SEER as 
determined from her death certificate. Survival was calculated as the numbers of months 
between the most recent MHOS she completed before cancer diagnosis and date of death.
SF-36/VR-12—HRQOL measures came from the Medical Outcomes Trust SF-36, which 
was included in the MHOS from 1998–2005.10 If a woman completed more than one 
MHOS, the closest MHOS before the date of diagnosis was selected. There are 8 subscales 
in the SF-36: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, 
Mental Health, Role-Emotional, and Social Functioning.2 The instrument also has two 
summary scores: the Physical Component Summary (PCS) and Mental Component 
Summary (MCS), which were created from the 8 subscales described above. Both summary 
and subscale scores were normed with means of 50 and standard deviation (SD) of 10 in the 
U.S general population2, 11, 12
MHOS cohorts from 2006–2013 completed the Veterans RAND-12 (VR-12) instrument, 
which includes 12 items reflecting the same 8 SF-36 subscales and PCS and MCS described 
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above.11, 12 Using an NCI-provided algorithm to create comparable subscale and summary 
scores (Selim, A., Rogers, W., Qian, S., Rothendler, J. A., Kent, E. E., Kazis, L. E. A New 
Algorithm to Build Bridges Between two Patient-Reported Health Outcome Instruments: 
The MOS SF-36® and the VR-12 Health Survey (under review)), we combined data for 
women who completed the SF-36 in 1998–2005 with women who completed the VR-12 in 
2006–2013. Higher SF-36/VR-12 scores across all 10 scales indicate better HRQOL.2
Global Health—We included two single-item global health questions in our study. The 
first asked, “In general, would you say your health is: excellent, very good, good, fair, or 
poor?” The second question was, “In general, compared to other people your age, would you 
say that your health is: excellent, very good, good, fair or poor?” Excellent was used as the 
reference category for all models.
Activities of Daily Living (ADLs)—We assessed associations between performance on 
Katz’s basic ADLs (e.g., dressing, bathing, eating, getting in or out of chairs, walking and 
using the toilet) and survival.13 Each question was worded as, “Because of a health or 
physical problem, do you have any difficulty doing the following activities without special 
equipment or help from another person?” and response options included, “No, I do not have 
difficulty,” “Yes, I have difficulty,” and “I am unable to do this activity.” ADLs were 
evaluated in separate models, adjusting for demographic, comorbid, and treatment 
characteristics. “No, I do not have difficulty,” was the reference category for all models, and 
“Yes, I have difficulty,” and “I am unable to do this activity” were collapsed into one group 
given the very small proportion of women in the last group.
Statistical Analysis
Unadjusted comparisons of demographic, socioeconomic, comorbid, and treatment 
characteristics between women who did and did not have surgery were assessed using t-test 
and chi-square tests. Multivariable logistic regression was used to calculate associations 
between pre-diagnosis HRQOL (using the 10 SF-36 measures) and the odds of receiving 
surgery, adjusting for covariates listed in Table 1. For survival analyses, unadjusted 
comparisons were performed between those who died and those who were alive at the end of 
follow-up (results not shown). Multivariable Cox-Proportional hazards models were used to 
examine associations between pre-diagnosis HRQOL (using the 10 SF-36 measures, two 
single-item HRQOL measures and 6 ADLs) and survival, adjusting for covariates listed in 
Table 1, including whether or not surgery was performed. For all models, SF-36 HRQOL 
scores were analyzed in 5-point increments, which are considered clinically meaningful for 
the instrument. For each outcome, models were stratified by time between the HRQOL 
survey and cancer diagnosis: less than and greater than 2 years.
Our sample included 199 women who received surgery and 295 deaths. Given the standard 
of 10 or more events per covariate included in a multivariable Cox Proportional Hazards 
model, our models with 18 covariates were appropriate.14 We performed sensitivity analyses 
reducing the number of socioeconomic factors and comorbidities adjusted for in both 
models, which yielded similar results. We computed adjusted odds ratios (OR), hazard ratios 
(HR) and 95% confidence intervals (CI) for each estimate. With our sample size we had an 
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80% power to detect an effect size of 0.53 for the outcome of surgery, and a HR of 2.8 or 
greater for the outcome of survival. Analyses were performed in SAS 9.3 with 2-tailed 
statistical tests.
Results
Participant characteristics
Demographics characteristics and comorbidities, overall and by receipt of surgery are 
presented in Table 1. All women had advanced stage (SEER ‘distant’: stage 3–4) disease. 
The surgery group had a greater proportion of women who were younger, married, and had 
college level or higher education. Hypertension and heart disease were also less common in 
the surgery group.
We compared women who were alive at the end of follow-up to those who had died. Race, 
geographic region, education, comorbidity and marital status were similarly distributed. 
Women alive at the end of follow up unsurprisingly had lower rates of smoking (18% vs 
32%, p<.01), higher rates of surgery (80% vs. 46%, p<.01), and were younger at the time of 
diagnosis (76 vs 79 years, p<.04).
Median time from HRQOL assessment to date of cancer diagnosis was 33 months with an 
interquartile range of 13 to 68 months. There were 216 (58%) women with HRQOL 
assessments more than 2 years prior to cancer diagnosis and 158 (42%) women with 
assessments occurring within 2 years of diagnosis.
Surgery
In the overall cohort, better HRQOL was significantly associated with increased odds of 
receiving surgery with adjusted ORs ranging from 1.05 to 1.72 (Table 2). As higher scores 
on SF-36/VR-12 measures indicate better HRQOL, all ORs were above 1.0. That is, 5-point 
increases in HRQOL were associated with increased odds of receiving surgery. We observed 
statistically significant associations between surgery and better PCS, and SF-36 subscales of 
Physical Function, General Health, Mental Health, and Vitality. For example, adjusting for 
patient demographics, comorbidities and treatment characteristics, a 5-point increase in 
patient-reported Vitality was associated with a 21% increase in the odds of receiving 
surgery. In general, the magnitude of adjusted ORs were larger among individuals with 
HRQOL assessed more than two years before diagnosis, particularly for the General Health 
domain with an adjusted OR of 1.72 (95% CI 1.29–2.30). Among the statistically significant 
measures, those with the most consistent estimates regardless of time between survey and 
diagnosis were the subscales of Mental Health and Vitality.
Of note, in the multivariable models, no comorbid conditions were significantly associated 
with surgery with the exception of inflammatory bowel disease, which was negatively 
associated with the odds of receiving surgery (OR: 0.14, 95% CI 0.03–0.72) and was very 
rare in our cohort.
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Overall Survival
Adjusted HRs for 5-point increments in PCS, MCS and the 8 SF-36 subscales are shown in 
Table 3. Most HR estimates were below 1.0. That is, as HRQOL increased, hazards of death 
decreased. No HRs were statistically significant at the 0.05 level. Results were similar when 
stratified by time between survey and diagnosis, with no statistically significant associations. 
When we stratified survival analyses by receipt of surgery, HRs were similar in magnitude to 
overall analyses with the exception of Physical Function (results not shown). That is, among 
women who received surgery, a 5-unit increase in Physical Function was significantly 
associated with a 2.2% decrease in the hazard of death (p=0.03). In this stratified analysis, 
most SF-36 measures had a similar direction of effect, but associations were non-significant.
The first single-item global health measure, poor health (compared to excellent) was 
associated with a 59% increase in the hazard of death, but this was not statistically 
significant (p=0.39). Reporting fair, good or very good health (compared to excellent) 
demonstrated a similar relationship with increased hazards of death (HRs of 1.36, 1.01 and 
1.05, respectively), but these were also not statistically significant. Similar HRs were seen 
for the other single-item question - comparing one’s health to others. Reporting poor 
(compared to excellent) health was associated with a 52% increase in the hazard of death 
(p=0.44). Reporting fair, good or very good health was not significantly associated with 
increased hazard of death, with HRs of 1.35, 1.00 and 1.03, respectively. As worse health 
was associated with increased hazard of death, both global HRQOL questions had HRs 
above 1.0.
Self-reporting that one experienced “some difficulty” in completing any of the 6 ADLs 
compared to having “no difficulty” was associated with increases in the hazard of death. For 
example, reporting some difficulty dressing oneself or eating was associated with adjusted 
HRs of 1.72 (95% CI: 0.99–2.96) and 1.75 (95% CI: 0.76–4.06), respectively. Once we 
collapsed the two ADL difficulty response categories (i.e., some difficulty and unable to do), 
HRs remained large in magnitude, but statistically non-significant (Table 3). However, 
reporting any difficulty using the toilet was associated with nearly twice the hazard of death 
with an adjusted HR of 1.81 (95%CI 1.03–3.19, p=0.04), which was statistically significant 
(Table 3).
Discussion
We sought to determine the relationship of self-reported HRQOL measures assessed prior to 
cancer diagnosis with likelihood of receiving surgery and with overall survival among a 
cohort of Medicare beneficiaries with advanced stage epithelial ovarian cancer. Higher 
HRQOL scores on SF-36/VR-12 measures were associated with higher likelihood of 
undergoing surgery. The relationship between higher HRQOL measures and survival was 
not statistically significant, although likely underpowered. Estimates of difficulty with ADLs 
and shorter overall survival were also not statistically significant, with the exception of 
difficulty using the toilet.
This study is population-based and fills an important gap by including individuals who are 
generally underrepresented in ovarian cancer HRQOL studies. Compared to the two GOG 
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trials, where at least 80% of the populations were younger than 70 years, in this cohort 94% 
of patients are over 70 years. As the incorporation of patient-reported data becomes more 
important in cancer care,8 data from older populations who make up an increasing 
proportion of cancer patients is vital. Our cohort also contained twice the proportion of 
racial/ethnic minorities included in GOG trials and a higher percentage of low-income 
women.
In this study, higher pre-diagnosis HRQOL was associated with greater odds of receiving 
surgery, adjusting for known indicators such as age and comorbidity. In addition, for this 
cohort of older women, patient-reported HRQOL was more predictive of having surgery, 
than comorbid conditions. It may be that patient-reported measures like Vitality more 
accurately align with global assessments of fitness for surgery made between patients and 
providers, than comorbidities alone. This may especially be the case among older women. 
Interestingly, the HRQOL and surgery relationship was strongest in the women where 
HRQOL was measured greater than 2 years before diagnosis. Given that the direction of 
effect was the same in both recent and older surveys, the statistical difference may be due to 
the larger sample size in the group with older surveys. In addition, those reporting decreased 
HRQOL further out from diagnosis may have experienced poor physical health for longer 
putting them at increased risk of death. Patient-reported HRQOL at the population-level can 
fill gaps to better understand treatment patterns of seemingly similar patients at the regional 
and national level.
We did not find statistically significant associations between pre-diagnosis HRQOL and 
overall survival. This is in contrast to two prior landmark studies, where women in the 
lowest HRQOL score quartiles experienced significantly shorter overall survival. Wenzel et 
al in 200515 and von Gruenigen et al in 20123 reported on the relationship between HRQOL 
measures and overall survival in ovarian cancer patients enrolled in two gynecologic 
oncology group (GOG) clinical trials. Both studies included over 400 participants. Important 
differences between the studies and our current study are the choices of HRQOL measures 
and timing of surveys. The previous studies used the Functional Assessment of Cancer 
Therapy-Ovarian (FACT-O), an ovarian cancer-specific instrument, and the Physical Well-
Being domain of the FACT-General to measure HRQOL. Our study used the generic SF-36/
VR-12 measures of HRQOL included in the MHOS. Cancer specific measures such as the 
FACT-O and FACT-G may be more appropriate assessments of disease and symptom burden 
associated with survival, compared to generic HRQOL assessments such as the SF-36/
VR-12. In addition, although we had a similar sample size as these clinical trials, the effect 
sizes (HR0.93 – 0.99) in our model suggested we would need over 7,000 cases to find 
statistical significance when modeling HRQOL linearly, as we chose to do.
In addition, timing of baseline HRQOL assessments in previous studies occurred after 
enrollment in clinical trials, which occurred after diagnosis and initial surgery. In our study, 
better HRQOL was associated with going on to receive surgery and surgery is associated 
with improved survival. Therefore, we imagined this relationship would bolster the 
connection between HRQOL and survival. One potential reason this did not occur may be 
the longer time interval between survey and diagnosis and the greater demographic diversity 
of our sample. With a more heterogeneous population, the standard deviations (SD) of 
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SF-36/VR-12 scores were wider than those reported in clinical trials. This, along with a 
smaller sample size and a lack of information on extent of surgery, limits the strength of 
associations between HRQOL and overall survival in this study.
A notable limitation of our study is the lack of available data on extent of surgical effort or 
receipt of chemotherapy. SEER-MHOS participants are enrolled in Medicare Advantage 
plans, not fee-for-service Medicare, and therefore not linked to Medicare billing claims. Due 
to this, the SEER-MHOS dataset does not include treatment or comorbidity information 
beyond what is self-reported in SEER and the MHOS.
In addition, our sample was limited to adults diagnosed with ovarian cancer aged 65 years 
and older, given the Medicare framework. The convenience nature of this dataset, which 
combined independently collected data for original purposes not related to HRQOL and 
cancer research may have introduced biases we cannot control for. The MHOS randomly 
selects 1000–1200 from each managed care plan. Women in our study were also enrolled in 
managed care plans, which may not be generalizable to Medicare fee-for-service 
beneficiaries. Evidence comparing health status between managed care and Medicare fee-
for-service beneficiaries is not consistent across previous studies.2, 16–18 Furthermore, 
comorbid conditions adjusted for in our analyses were obtained by self-report in the MHOS 
and do not have clinical confirmation. Although confirmation of death in SEER-MHOS is 
considered reliable,19 we could not determine whether death was caused by ovarian cancer, 
which does not allow us to evaluate associations between HRQOL and ovarian cancer-
related mortality.
This national, population-level data on pre-diagnosis HRQOL of women with ovarian cancer 
suggests baseline HRQOL is associated with who goes on to receive surgery, which is the 
strongest determinant of survival for this disease. Pre-diagnosis HRQOL may also be 
associated with survival, but we could not confirm statistical associations in our analyses. 
This work supports the continued integration of HRQOL information into routine clinical 
assessments. In ovarian cancer, this may aid in critical decision making such as initiation of 
neo-adjuvant chemotherapy versus upfront surgery. These results are especially important 
for older women, who are currently underrepresented in ovarian cancer clinical trials.
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Highlights
• SEER-MHOS is a linked national data set of cancer and 
HRQOL data.
• Women with ovarian cancer who had HRQOL surveys 
prior to diagnosis were analyzed.
• Pre-diagnosis HRQOL was predictive of receiving 
surgery.
• Pre-diagnosis HRQOL was not associated with overall 
survival.
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Table 4
Association between Activities of Daily Living before Cancer Diagnosis and Overall Survival
Difficulty with
Activities of Daily
Livinga
aHRb
95% CI
p-
value
Bathing 1.47 0.98–2.19 0.07
Dressing 1.55 0.96–2.49 0.08
Eating 1.53 0.74–3.13 0.25
Chair to Standing 1.31 0.93–1.85 0.12
Walking 1.11 0.79–1.55 0.54
Toilet Use 1.81 1.03–3.19 0.04
a
Referent group for each activity of daily living is response of “no difficulty” with the designated activity, and exposure group is response of having 
‘difficulty’ or being ‘unable to do’ the activity.
b
Hazard ratio from cox proportional hazard model adjusted for all variables in Table 1.
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